JASPER THERAPEUTICS, INC. Depreciation and Amortization
JASPER THERAPEUTICS, INC. (JSPR) reported Depreciation and Amortization of $1.11 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:DepreciationDepletionAndAmortization · last filed 2024-03-05
- JASPER THERAPEUTICS, INC. depreciation, depletion and amortization for the quarter ending 2023-12-31 was $283.00K, a 3.66% increase year-over-year.
- JASPER THERAPEUTICS, INC. depreciation, depletion and amortization for the quarter ending 2023-09-30 was $300.00K, a 0.00% change year-over-year.
- JASPER THERAPEUTICS, INC. depreciation, depletion and amortization for the quarter ending 2022-12-31 was $273.00K.
- JASPER THERAPEUTICS, INC. depreciation, depletion and amortization for the quarter ending 2022-09-30 was $300.00K.
- JASPER THERAPEUTICS, INC. depreciation, depletion and amortization for fiscal 2023 was $1.11M, a 13.64% increase from fiscal 2022.
- JASPER THERAPEUTICS, INC. depreciation, depletion and amortization for fiscal 2022 was $975.00K.
| Period end | Depreciation, Depletion and Amortization 3 month | Depreciation, Depletion and Amortization 6 month | Depreciation, Depletion and Amortization 9 month | Depreciation, Depletion and Amortization 12 month |
|---|---|---|---|---|
| 2023-12-31 | $283.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $583.00K derived: sum of 2 quarters · filed 2024-03-05 | $1.11M 10-K · filed 2024-03-05 | |
| 2023-09-30 | $300.00K 10-Q · filed 2023-11-09 | $825.00K 10-Q · filed 2023-11-09 | ||
| 2022-12-31 | $273.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $573.00K derived: sum of 2 quarters · filed 2024-03-05 | $975.00K 10-K · filed 2024-03-05 | |
| 2022-09-30 | $300.00K 10-Q · filed 2023-11-09 | $702.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |